



Windlas Biotech Ltd. IPO

Aug 4 to 6

Windlas Biotech Ltd. is coming out with a fresh public issue to raise ₹ 401.54 crores from the market.

Key details of the issue:

- **Issue opens – Aug 4 (Wednesday)**
- **Issue closes – Aug 6 (Friday)**
- Issue size – ₹ 401.54 crores
- Price band – ₹ 448 – 460 per equity share
- Bid lot – 30 shares and in multiples thereof

And here are some details of the company and further details on the **Windlas Biotech Ltd.** IPO issue.

Company details:

Windlas Biotech Limited is among the top five players in the domestic pharmaceutical formulations Contract Development and Manufacturing Organization (CDMO) industry in India in terms of revenue (Source: *CRISIL Report*).

With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including high-potency controlled substances and low-solubility, they provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost.

In Fiscal 2020, their market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: *CRISIL Report*). In addition to providing services and products in the CDMO market, they also sell their own branded products in the trade generics and OTC markets as well as export generic products to several countries.

They have significant experience in developing and manufacturing generic fixed-dose combinations. Their focus has currently been on launching new complex generic products in the chronic therapeutic category linked to lifestyle-related disorders.

They have three distinct strategic business verticals:

- CDMO services and products
- Domestic trade generics and over-the-counter brands
- Exports

They currently own and operate four manufacturing facilities located in Dehradun, Uttarakhand.

Issue size: ₹ 401.54 crores

Issue break-up:

- QIB – 50% of the offer – ₹ 200.77 crores
- NIB – 15% of the offer – ₹ 60.23 crores
- RET – 35% of the offer – ₹ 140.54 crores

Listing: NSE and BSE

Registrar: Link Intime India Private Limited

UPI: All retail applications through brokers are compulsorily in UPI mode

Not a Sharekhan customer?

Not a Sharekhan customer, but still want to apply for the **Windlas Biotech Ltd.** IPO? Become a Sharekhan customer in just 15 mins* by tapping [here](#) and take it from there! (* T&C apply)